

RAPID ALERT

DRAP ALERT No: I/S/02-25-19

CRACKDOWN AGAINST FALSIFIED/SPURIOUS DRUGS

Date: 17th February, 2025

Target Audience:

- Regulatory Field Force of DRAP and Provincial Drug Control departments.
- Healthcare Professionals
- Pharmacies and medical stores

Problem Statement:

Drug Testing Laboratory, Sindh has informed to Drug Regulatory Authority of Pakistan that samples of following products taken by various provincial drug inspectors, have been declared '*Spurious*' (falsified). Moreover, the following firms and their associated products were found to be fictitious. The details of the reports are as below:

Sr#	Product name	Batch/Lot No.	Stated Manufacturer	Test Results
1.	Eyosef 250mg capsule (Cephradine)	HF-001	M/s East Pharmaceuticals, 19-Km Sheikhupura Road, Lahore.	Spurious, Cephradine not identified
2.	Mirzpan Suspension 100mg/5ml (Cefixime)	0008	M/s Miraz Pharma, Plot No: 23 Kasur Industries, Kasur.	Spurious, Cefixime not identified
3.	Mirzolam Tablet 0.5mg (Alprazolam)	0007	M/s Miraz Pharma, Plot No: 23 Kasur Industries, Kasur.	Spurious, Alprazolam not identified
4.	Bromalax Tablet 3mg (Bromazepam)	B-01	M/s Brom Pharmaceuticals (Pharmaceutical Industries), 21-Km Ferozpur Road, Lahore.	Spurious, Bromazepam not identified
5.	Malixime Suspension 200mg/5ml (Cefixime)	78011	M/s Menakline Pharma, S Site Plot 11, Korangi Industrial Area, Karachi.	Spurious, Cefixime not identified
6.	Lexopam Tablet 3mg (Bromazepam)	B-01	M/s Porm Pharmaceuticals (Pharmaceutical Industries), 220 Industrial Estate Hayatabad, Peshawar.	Spurious, Bromazepam not identified

Q

B



	OF PAKS			
7.	Zionex Tablet 0.5mg (Alprazolam)	0032	M/s Multicare Pharmaceutical, Plot # 23, Korangi Industrial Area, Karachi.	Spurious, Alprazolam not identified
8.	Tramaking-225 Mega tablet 225mg (Tramadol HCl)	TRD2002	Name of Manufacturer not mentioned.	Spurious
9.	Alcoxime Suspension 100mg/5ml (Cefixime)	A2011	M/s Alpine Laboratories (Pvt.) Ltd: Plot# A-41, S.I.T.E Indsutrial Area, Sector 3 North Karachi Super Highway 75500- Pakistan.	Spurious, Cefixime not identified

Risk Statement:

Falsified products having no active ingredient or identification of manufacturer pose a great risk to the health of patient and can cause adverse drug reactions or may lead to therapy failure that can result in fatal consequences.

Action Initiated: -

The Regulatory Field Force has been directed to increase surveillance throughout the supply chain to confiscate the mentioned products. All Pharmacists, chemists, and other healthcare professionals working at distributions, pharmacies, healthcare facilities, and other aspects of the supply chain system should immediately check the stock, and information related to the suppliers of such products should be provided to the Regulatory field force (DRAP, Provincial Drug Control Departments) to ensure the removal of these product from the circulation.

Advice for Healthcare Professionals: -

DRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using <u>Adverse Event Reporting Form</u> or online through this <u>link</u>. Further information on reporting problems to DRAP is available on this <u>link</u>.



+ 92 051 9255969

A



Advice for Consumers:

Consumers should not use these products and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre.

All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.



